Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01986673
Recruitment Status : Completed
First Posted : November 18, 2013
Last Update Posted : January 27, 2014
Sponsor:
Information provided by (Responsible Party):
Strategic Science & Technologies, LLC

Brief Summary:
The purpose of this study is to evaluate how a single dose of sildenafil cream (SST-6006) is absorbed and eliminated by the body, with and without the use of a condom, compared to a single oral sildenafil dose and to evaluate the safety of sildenafil cream.

Condition or disease Intervention/treatment Phase
Healthy Drug: 5% Sildenafil Cream (SST-6006) Drug: Oral Sildenafil 50 mg Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : October 2013
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 5% Sildenafil Cream (SST-6006)
5% Sildenafil Cream
Drug: 5% Sildenafil Cream (SST-6006)
5 % Sildenafil Cream

Active Comparator: Oral Sildenafil 50 mg
Oral Sildenafil 50 mg
Drug: Oral Sildenafil 50 mg
Oral Sildenafil 50 mg




Primary Outcome Measures :
  1. Cmax, Tmax, AUC 0-tlast, AUC 0-t, Kel, AUC0-inf, t1/2, CL/F [ Time Frame: 32 hours ]

Secondary Outcome Measures :
  1. Adverse Events [ Time Frame: 7 to 10 days ]
    Number of subjects experiencing TEAEs.

  2. Clinical Chemistry Tests [ Time Frame: 1 day ]
    Changes from baseline in clinical chemistry values

  3. Vital Signs [ Time Frame: 1 day ]
    Vital sign changes from pre-dose



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Willing and able to sign and date the written informed consent form (ICF) before any study-specific screening procedures are performed
  2. Men between the ages of 18 to 55 years, inclusive
  3. Body mass index (BMI = weight [kg]/height [m]2) between 18.0 to 30.0 kg/m2, inclusive and body weight of at least 50 kg
  4. Nonsmoker or past smoker who has been abstinent for 6 months before study Day 1
  5. Have a high probability for compliance with and completion of the study, in the opinion of the Principal Investigator
  6. Healthy as determined by the investigator based on medical history, physical examination, clinical laboratory tests, vital sign measurements, and a normal 12-lead ECG
  7. Resting supine systolic blood pressure between 90 and 140 mmHg and resting supine diastolic blood pressure between 50 and 90 mmHg
  8. Must be able to achieve a successful erection

Exclusion Criteria:

  1. Presence or history of any disorder that may prevent the successful completion of the study
  2. Presence of any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, genitourinary, or psychiatric disease, or other unstable medical condition
  3. Subjects with a history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to study Day 1, or a history of coronary disease causing angina
  4. Subjects with retinitis pigmentosa and subjects with sickle cell anemia or related anemias, even if they feel clinically well at the time of screening. Subjects with retinitis pigmentosa will be identified by specifically asking whether they have the condition, if there are visual signs and symptoms of the condition (including questioning subjects as to whether they have difficulty seeing at night or in low light, and if they have any visual field deficits that indicate a loss of peripheral or central vision), or if there is a family history
  5. Subjects with anatomical deformations of the penis such as angulation, cavernosal fibrosis or Peyronie's disease
  6. History of orthostatic hypotension or orthostatic hypotension present at the screening visit, defined as a drop in systolic blood pressure greater than 20 mm Hg and a drop in diastolic blood pressure greater than 10 mm Hg with a change in position from supine to standing
  7. A history of erectile dysfunction or a prostatectomy
  8. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article
  9. Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study Day 1
  10. History of drug abuse within 1 year before study Day 1
  11. History of alcoholism within 1 year before study Day 1, admitted alcohol abuse, or average consumption of more than 2 standard units of alcohol per day (a standard unit equals 12 ounces of beer, 1½ ounces of 80-proof alcohol, or 6 ounces of wine)
  12. Use of any prescription drugs within 28 days before study Day 1, or over-the-counter drugs, including herbal supplements (except for the occasional use of acetaminophen [Tylenol] and vitamins) within 14 days before study Day 1. If the subject takes any prescription or OTC drugs at the direction of a health care provider, that provider should be consulted before medications are stopped for the purposes of study participation.
  13. Positive serologic findings for human immunodeficiency virus antibodies (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C antibodies (HCV)
  14. Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, and opiates) or alcohol screen
  15. Participation in a clinical trial within 30 days before study Day 1
  16. Consumption of any caffeine-containing products (eg, coffee, tea, chocolate, or soda) or alcoholic beverages within 48 hours before study Day 1
  17. Consumption of grapefruit or grapefruit-containing products within 72 hours before study Day 1
  18. Any skin breaks, irritation, or lesions present in the area to which the cream will be applied, assessed at screening and check-in
  19. A drug or food allergy which in the opinion of the Investigator contraindicates participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01986673


Locations
Layout table for location information
United States, Florida
SST Clinical Site
Miami, Florida, United States
Sponsors and Collaborators
Strategic Science & Technologies, LLC
Layout table for additonal information
Responsible Party: Strategic Science & Technologies, LLC
ClinicalTrials.gov Identifier: NCT01986673    
Other Study ID Numbers: SST-6006-001-01
First Posted: November 18, 2013    Key Record Dates
Last Update Posted: January 27, 2014
Last Verified: January 2014
Keywords provided by Strategic Science & Technologies, LLC:
Pharmacokinetic Characterization
Additional relevant MeSH terms:
Layout table for MeSH terms
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents